Compare IRS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
Current Price
Current Price
| Metric | IRS | VOR |
|---|---|---|
| Founded | 1943 | 2015 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1998 | 2021 |
| Metric | IRS | VOR |
|---|---|---|
| Price | $14.65 | $23.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | 145.5K | ★ 807.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.87 | $1.90 |
| 52 Week High | $19.14 | $49.95 |
| Indicator | IRS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 67.09 |
| Support Level | $14.05 | $21.75 |
| Resistance Level | $15.99 | $24.34 |
| Average True Range (ATR) | 0.41 | 1.27 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 29.15 | 90.16 |
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.